Clinical Trials on Esophageal and Gastric Varices in New Zealand

Total 756 results

Institute of Liver and Biliary Sciences, India

Completed

To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices.

Cirrhosis With Esophageal Varices

India
Debiovision

Completed

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

Portal Hypertension | Esophageal Varices | Gastric Varices | Esophageal Bleeding

United States
Institute of Liver and Biliary Sciences, India

Withdrawn

To Compare the Efficacy of Endoscopic Ultrasound Assisted Endoscopic Glue Injection and Conventional Endoscopic Injection Therapy for Prevention of Gastric Variceal Rebleed

Bleeding Gastric Varices

India
Institute of Liver and Biliary Sciences, India

Not yet recruiting

Spleen Stiffness as a Measure to Assess the REsponse to β Blocker Therapy (SPARE-B)

High Risk Esophageal Varices

India
Institute of Liver and Biliary Sciences, India

Not yet recruiting

To Compare the Safety and Efficacy of Balloon Occluded/Plug Assisted Retrograde Transvenous Obliteration With Endoscopic Variceal Obturation for Primary Prophylaxis of Gastric Varices With Large Spontaneous Shunt

Liver Cirrhosis

India
Govind Ballabh Pant Hospital

Completed

A Trial of Somatostatin With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding (AVB-EVL+S)

Cirrhosis | Portal Hypertension | Acute Bleeding Esophageal Varices

India
Institute of Liver and Biliary Sciences, India

Completed

Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.

Chronic Liver Disease

India
Galectin Therapeutics Inc.

Active, not recruiting

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NAVIGATE)

Cirrhosis | NASH - Nonalcoholic Steatohepatitis | Prevention of Esophageal Varices

United States, France, Spain, Australia, Canada, Israel, Puerto Rico, Belgium, Argentina, Chile, Germany, Korea, Republic of, Mexico, Poland, United Kingdom
Govind Ballabh Pant Hospital

Completed

Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)

Cirrhosis

India
Institute of Liver and Biliary Sciences, India

Unknown

Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis

Cirrhosis

India
Institute of Liver and Biliary Sciences, India

Completed

Early Primary Prophylaxis of Esophageal Varices

Cirrhosis

India
Institute of Liver and Biliary Sciences, India

Recruiting

Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices

Liver Cirrhosis

India
Institute of Liver and Biliary Sciences, India

Completed

Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure

Acute-On-Chronic Liver Failure

India
Institute of Liver and Biliary Sciences, India

Completed

Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices

Acute on Chronic Liver Failure

India
National Institute of Diabetes and Digestive and...
Yale University

Completed

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

Liver Cirrhosis | Esophageal and Gastric Varices | Portal Hypertension

United States, Spain, United Kingdom
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditions

United States
Al B. Benson, III, MD
Celgene Corporation; Big Ten Cancer Research Consortium

Completed

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Gastric Cancer | Gastro-Esophageal Junction Adenocarcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Adenocarcinoma | Recurrent Gastric Carcinoma | Esophageal Undifferentiated Carcinoma | Gastric Squamous Cell Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IV Esophageal Adenocarcinoma | Stage... and other conditions

United States
Australasian Gastro-Intestinal Trials Group
National Health and Medical Research Council, Australia; Canadian Cancer Trials... and other collaborators

Active, not recruiting

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEIIa)

Gastro-Oesophageal Cancer

Korea, Republic of, Australia, Taiwan, New Zealand, United States, Canada, Japan
Australasian Gastro-Intestinal Trials Group

Recruiting

A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study (PALEO)

Oesophageal Cancer

Australia, New Zealand
Western Sydney Local Health District

Recruiting

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study (ANZ UGI)

Gastric Cancer | Esophageal Neoplasms | Neuroendocrine Tumors | Gastric Adenocarcinoma | Cancer of Stomach | Oesophageal Cancer | Gastric Neoplasm | GIST | GI Cancer

Australia
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Carcinoma | Metastatic Gastric Carcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer... and other conditions

United States
University of Auckland, New Zealand
Health Research Council, New Zealand

Completed

Wool-derived Keratin Dressings for Venous Leg Ulcers (Keratin4VLU)

Varicose Ulcer

New Zealand
National Cancer Institute (NCI)

Terminated

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Terminated

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Gastric Cancer | Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Junction Cancer | Gastric Tumor | Gastroesophageal Junction Adenocarcinoma | GastroEsophageal Cancer | Esophageal Tumor | Esophagogastric Tumors | Gastroesophageal Junction Tumor

United States
James J. Peters Veterans Affairs Medical Center

Unknown

GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals

Gastro Esophageal Reflux Disorder

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

Gastric Cancer | Esophageal Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Gastric Cancer | Esophageal Cancer

United States
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIC Breast Cancer | Adenocarcinoma of the Gastroesophageal Junction | Recurrent Breast Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage IIIC Gastric... and other conditions

United States
Novartis Pharmaceuticals

Completed

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Advanced Gastric Cancer | Gastro-esophageal Junction Cancer

United States, France, Italy, Taiwan, United Kingdom, Turkey, Germany, Singapore, Australia, Russian Federation, Korea, Republic of, Switzerland, Netherlands, Canada
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute; United States Department of Defense; Boehringer... and other collaborators

Completed

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Gastric Cancer | Esophageal Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer

Gastric Cancer | Esophageal Cancer

United States
Taiho Oncology, Inc.

Terminated

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST)

Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction

Belgium, Spain, United States, Italy, Estonia, Russian Federation, Bulgaria, Hungary, Croatia, Israel, Mexico, Poland, Portugal, Romania, South Africa, Ukraine, United Kingdom, Brazil, Germany, Argentina
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Gastric Adenocarcinoma | Esophagogastric Cancer | Gastroesophageal Junction Adenocarcinoma | Esophagus Cancer | Gastroesophageal Junction Squamous Cell Carcinoma

United States
Fox Chase Cancer Center
National Comprehensive Cancer Network; Puma Biotechnology, Inc.

Recruiting

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Gastric Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastric Adenocarcinoma | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8 | Clinical... and other conditions

United States
Bristol-Myers Squibb

Completed

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

France, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

Gastric Cancer | Esophageal Cancer

United States
Bristol-Myers Squibb
National Cancer Institute (NCI)

Completed

BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy

Gastric Cancer | Esophageal Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Gastric Cancer | Esophageal Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy

Gastric Cancer | Esophageal Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer

Gastric Cancer | Esophageal Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
Roswell Park Cancer Institute
Pfizer

Terminated

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

Gastric Cancer | Esophageal Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer

Gastric Cancer | Esophageal Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Gastric Cancer | Esophageal Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; Oncolys BioPharma Inc

Not yet recruiting

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach

Gastric Cancer | Esophageal Cancer

United States, South Africa, Puerto Rico

Clinical Trials on Esophageal and Gastric Varices in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations